Yuki Katayama, Tadaaki Yamada, Ryo Sawada, Hayato Kawachi, Kenji Morimoto, Satoshi Watanabe, Kageaki Watanabe, Takayuki Takeda, Yusuke Chihara, Shinsuke Shiotsu, et al. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer. The oncologist. 2024
Satoshi Watanabe, Naoki Furuya, Atsushi Nakamura, Jun Shiihara, Ichiro Nakachi, Hisashi Tanaka, Mika Nakao, Koichi Minato, Masahiro Seike, Shinichi Sasaki, et al. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). European journal of cancer (Oxford, England : 1990). 2023. 197. 113469-113469
Hiroshi Moro, Yuuki Bamba, Kei Nagano, Mariko Hakamata, Hideyuki Ogata, Satoshi Shibata, Hiromi Cho, Nobumasa Aoki, Mizuho Sato, Yasuyoshi Ohshima, et al. Dynamics of iron metabolism in patients with bloodstream infections: a time-course clinical study. Scientific Reports. 2023. 13. 1
Tadaaki Yamada, Yasuhiro Goto, Hiroshi Tanaka, Hideharu Kimura, Koichi Minato, Hiroshi Gyotoku, Takeshi Honda, Satoshi Watanabe, Kenji Morimoto, Fumiaki Kiyomi, et al. A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study. European journal of cancer (Oxford, England : 1990). 2023. 195. 113373-113373
Rika Moriya, Satoshi Hokari, Yasuyoshi Ohshima, Ryoko Suzuki, Asuka Nagai, Nobuhiro Fujito, Atsunori Takahashi, Nobumasa Aoki, Satoshi Watanabe, Toshiyuki Koya, et al. Erratum to "Continuous positive airway pressure treatment reduces renal tubular damage in patients with obstructive sleep apnea: A retrospective single-center cohort study" [Sleep Med 106 (2023) 106-115]. Sleep medicine. 2023. 109. 190-191
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu, et al. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. 26. 9. 2244-2256
日本臨床腫瘍学会
, International association for the study of lung cancer
, American association for cancer research
, 日本癌学会
, 日本呼吸器内視鏡学会
, 日本肺癌学会
, 日本呼吸器学会
, 日本内科学会